After finishing at $34.74 in the prior trading day, Immunovant Inc (NASDAQ: IMVT) closed at $33.97, down -2.22%. In other words, the price has decreased by -$0.77 from its previous closing price. On the day, 837807 shares were traded.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Ratios:
Our goal is to gain a better understanding of IMVT by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 22.14 and its Current Ratio is at 22.14. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, JP Morgan on February 20, 2024, initiated with a Overweight rating and assigned the stock a target price of $51.
On February 15, 2024, Wolfe Research started tracking the stock assigning a Outperform rating and target price of $55.
On December 12, 2023, Deutsche Bank started tracking the stock assigning a Buy rating and target price of $50.Deutsche Bank initiated its Buy rating on December 12, 2023, with a $50 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Feb 22 when Salzmann Peter sold 13,454 shares for $36.15 per share. The transaction valued at 486,362 led to the insider holds 931,231 shares of the business.
Barnett Eva Renee sold 2,930 shares of IMVT for $105,920 on Feb 22. The Chief Financial Officer now owns 320,420 shares after completing the transaction at $36.15 per share. On Feb 22, another insider, Macias William L., who serves as the Chief Medical Officer of the company, sold 2,221 shares for $36.15 each. As a result, the insider received 80,289 and left with 330,952 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, IMVT now has a Market Capitalization of 4.94B and an Enterprise Value of 4.24B.
Stock Price History:
Over the past 52 weeks, IMVT has reached a high of $45.58, while it has fallen to a 52-week low of $14.05. The 50-Day Moving Average of the stock is 38.82, while the 200-Day Moving Average is calculated to be 30.19.
Shares Statistics:
The stock has traded on average 1.43M shares per day over the past 3-months and 1.12M shares per day over the last 10 days, according to various share statistics. A total of 130.33M shares are outstanding, with a floating share count of 60.74M. Insiders hold about 58.20% of the company’s shares, while institutions hold 46.32% stake in the company. Shares short for IMVT as of Feb 15, 2024 were 9.01M with a Short Ratio of 6.30, compared to 8.04M on Jan 12, 2024. Therefore, it implies a Short% of Shares Outstanding of 6.20% and a Short% of Float of 12.89%.
Earnings Estimates
Its stock is currently analyzed by 12 different market analysts. On average, analysts expect EPS of -$0.42 for the current quarter, with a high estimate of -$0.35 and a low estimate of -$0.49, while EPS last year was -$0.46. The consensus estimate for the next quarter is -$0.45, with high estimates of -$0.39 and low estimates of -$0.53.
Analysts are recommending an EPS of between -$1.7 and -$1.93 for the fiscal current year, implying an average EPS of -$1.79. EPS for the following year is -$1.85, with 12 analysts recommending between -$0.83 and -$2.25.
